Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NextCure ( (NXTC) ) has issued an update.
On July 10, 2025, NextCure, Inc. announced that its board of directors approved a one-for-twelve reverse stock split of its common stock, which will become effective on July 14, 2025. This move will result in every 12 shares being converted into one share, with no fractional shares issued. Stockholders will receive cash for any fractional shares based on the closing price before the effective date. The reverse split will also lead to adjustments in the company’s equity awards and incentive plans, impacting the exercise or conversion prices.
The most recent analyst rating on (NXTC) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on NextCure stock, see the NXTC Stock Forecast page.
Spark’s Take on NXTC Stock
According to Spark, TipRanks’ AI Analyst, NXTC is a Underperform.
NextCure’s overall stock score reflects significant financial challenges, including a lack of revenue and ongoing cash burn typical of early-stage biotech firms. The technical analysis suggests a bearish trend with potential volatility, while valuation metrics are unfavorable due to negative earnings. Despite a positive corporate event related to clinical trials, the company must urgently address its financial sustainability through partnerships or additional funding to enhance its long-term prospects.
To see Spark’s full report on NXTC stock, click here.
More about NextCure
Average Trading Volume: 233,135
Technical Sentiment Signal: Sell
Current Market Cap: $12.78M
Find detailed analytics on NXTC stock on TipRanks’ Stock Analysis page.